Iain Shaw has over 30 years of experience in the pharmaceutical industry, including over 15 years focused on 14C-enabled drug development.
Iain joined Quotient Sciences in 2008 as Director of Customer Service. Today, he is responsible for the portfolio of 14C programs that Quotient Sciences offers to address questions around drug metabolism and pharmacokinetics using human ADME, microADME, intravenous microtracer techniques, and Quotient Sciences' Synthesis-to-Clinic integrated ADME programs.
Prior to joining Quotient Sciences, Iain held early development program management, clinical development, and analytical positions at pharmaceutical companies and contract research organizations (CROs), including at Covance (now part of Fortrea) and PPL Therapeutics.
